Area of research
Genetics · Pulmonary and Respiratory Medicine
Research interest
Immunology Neuro Sciences Oncology Description of Research Interest The Laboratory of Molecular Neuro-Oncology investigates the biology and experimental therapy of various types of brain tumor. These tumors, notably glioblastomas, are among the most lethal neoplasms. Gliomas are paradigmatic for their ability to deeply infiltrate the surrounding healthy tissue, precluding definitive surgical resection and limiting the efficacy of other local therapies. The results achieved with traditional cancer therapies are poor because of defects in the apoptotic machinery of glioma cells, accounting for their resistance to irradiation and chemotherapy.
cIMPACT-NOW update 11: Proposal on adaptation of diagnostic criteria for IDH- and H3-wildtype diffuse high-grade gliomas and for posterior fossa ependymal tumors.
EANS-EANO guidelines on the extent of resection in gliomas.
RANO seizure working group-Tumor-Related Epilepsy Assessment Tool (RANO-TREAT) to assess seizure control for glioma treatment trials and clinical practice.
Associations of supramaximal resection with outcome in glioblastoma across age groups: A report of the RANO resect group.
The prognostic impact of
<i>CDKN2A/B</i>
hemizygous deletions in meningioma
Targeted next-generation sequencing-based sequencing of cell-free DNA in cerebrospinal fluid uncovers cancer-specific mutations in patients with brain cancer using a widely available panel.
Ethical considerations in randomization for neurosurgical oncology trials: A scoping review.
Prognostic Role of Ventricular Size and Its Dynamics in Patients With Leptomeningeal Metastasis From Solid Tumors.
Consensus statement on microglial and macrophage functions in gliomas.
Age and sex as risk factors for health-related quality of life outcomes in patients with glioma: a CODAGLIO 2.0 analysis.
European neuro-oncology quality assessment (ENOQUA): A European organization for the research and treatment of cancer (EORTC) brain tumor group research project.
Evaluation of Regorafenib in Newly Diagnosed and Recurrent Glioblastoma: GBM AGILE Phase II/III Bayesian Randomized Platform Trial.
A microenvironment-determined risk continuum refines subtyping in meningioma and reveals determinants of machine learning-based tumor classification.
Prognostic associations of steroid use in patients with glioblastoma: A population-based study
Long-Term Treatment With Interleukin-6 Receptor Inhibitor Tocilizumab in Myelin Oligodendrocyte Glycoprotein Antibody–Associated Disease
Association of proton pump inhibitor use with outcome of patients with recurrent glioblastoma
MOG Antibody Status Shapes Divergent Clinical Profiles And Therapeutic Responses In Chronic Relapsing Inflammatory Optic Neuropathy
Glioblastoma in adults: A Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions
Update to the RANO working group and EANO recommendations for the clinical use of PET imaging in gliomas
RANO criteria for response assessment of brain metastases based on amino acid PET imaging
Update to the RANO working group and EANO recommendations for the clinical use of PET imaging in gliomas
European Association of Neuro-Oncology guideline on molecular testing of meningiomas for targeted therapy selection.
The role of vorasidenib in the treatment of isocitrate dehydrogenase-mutant glioma.
RANO criteria for response assessment of brain metastases based on amino acid PET imaging.
Updated EANO guideline on rational molecular testing of gliomas, glioneuronal, and neuronal tumors in adults for targeted therapy selection-Update 1.
Leptomeningeal metastatic disease: new frontiers and future directions.
Benchmarking the efficacy of salvage systemic therapies for recurrent meningioma: A RANO group systematic review and meta-analysis to guide clinical trial design.
<scp>cIMPACT</scp> ‐ <scp>NOW</scp> update 11: Proposal on adaptation of diagnostic criteria for <scp>IDH</scp> ‐ and <scp>H3</scp> ‐wildtype diffuse high‐grade gliomas and for posterior fossa ependymal tumors
The clinical and molecular landscape of diffuse hemispheric glioma, H3 G34-mutant
A prognostic classification system for extent of resection in IDH-mutant grade 2 glioma: an international, multicentre, retrospective cohort study with external validation by the RANO resect group